Drug Discovery World

JANUARY 18, 2023

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System. . Bioavailability is defined as the fraction of drug reaching the bloodstream.

Bioavailability 52

Bioavailability In-Vitro Research Drugs 52

Outsourcing Pharma

AUGUST 8, 2022

The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.

Bioavailability 52

Bioavailability Branding Medicine Production 52

Pharmaceutical Technology

APRIL 7, 2023

Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV). In vitro data of EDP-323 showed a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B.

In-Vitro 276

In-Vitro Bioavailability Development Drugs 276

Pharma Mirror

APRIL 8, 2022

CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications. Both have stellar experience and track records in oncology research and development.

Bioavailability 130

Bioavailability Clinical Trials Clinical Trials Development 130

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.

Development 81

Development Drugs Manufacturing Immune Response 81

Pharmaceutical Technology

SEPTEMBER 23, 2022

While a handful of therapies have launched since then, late-stage pipeline therapies that are currently in development reveal that drug developers are exploring a broad set of mechanisms of action (MOAs), many of which are innovative, to tackle DES.

Development 147

Development Drugs Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JUNE 13, 2023

The company stated that the family of drug candidates of SERCA2a activators has similar mechanisms of action to those of istaroxime, a first-in-class dual mechanism therapy. In April 2023, the dual mechanism SERCA2a activator class of drug candidates received a patent from the European Patent Office.

Bioavailability 130

Bioavailability Protein Drugs Development 130

Drug Discovery World

SEPTEMBER 28, 2022

Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Register now to attend the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Key Learning Objectives:? To secure your place, register for FREE now . .

Drugs 52

Drugs Bioavailability Medicine 52

Drug Discovery World

SEPTEMBER 21, 2022

Register now to attend the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.

Drugs 52

Drugs Bioavailability Medicine 52

Drug Discovery World

SEPTEMBER 15, 2022

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. . This free event, Introduction into Fragment Based Drug Discovery, will be hosted by DDW and supported by WuXiAppTec. . To secure your place, register for FREE now .

Drugs 52

Drugs Bioavailability Medicine 52

XTalks

DECEMBER 5, 2022

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2

Bioavailability 97

Bioavailability FDA Approval Trials Drugs 97

Drug Discovery World

OCTOBER 5, 2022

Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds. . Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Learn how FBDD is being used as one strategy of hit identification within drug discovery.

Drugs 52

Drugs Bioavailability Medicine 52

Pharmaceutical Technology

JANUARY 17, 2023

Orphagen Pharmaceuticals has received a rare pediatric disease designation (RPDD) for OR-449 from the US Food and Drug Administration (FDA) to treat paediatric adrenocortical carcinoma (ACC). The SF-1 antagonist is also being developed to treat other cancers, which are known to express increased SF-1 levels.

Bioavailability 147

Bioavailability Clinical Trials Clinical Trials Clinical Development 147

Pharmaceutical Technology

FEBRUARY 13, 2023

Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drug delivery system that improves the drug’s bioavailability and solubility.

Drug Delivery Systems 130

Drug Delivery Systems FDA Approval Bioavailability Drug Delivery 130

Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.

Medicine 52

Medicine Bioavailability Clinical Development Trials 52

Pharmaceutical Technology

MAY 8, 2023

The approvals were granted for two Supplemental Applications to covert conditional approval to regular approval, and two Supplemental New Drug Applications to treat Waldenström’s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients.

Bioavailability 130

Bioavailability Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

MAY 2, 2023

Erasca has received the US Food and Drug Administration’s (FDA) fast track designation (FTD) for ERAS-801 to treat adults with glioblastoma (GBM) with epidermal growth factor receptor (EGFR) gene alterations.

Bioavailability 130

Bioavailability Clinical Development Gene Trials 130

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Marketing 40

Pharmaceutical Technology

APRIL 20, 2023

In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.

Bioavailability 130

Bioavailability Manufacturing Scientist Development 130

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. In principle, these compounds can achieve the fine balance required of modern drugs.

Drugs 40

Drugs Bioavailability Protein Research 40

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

Roots Analysis

MARCH 1, 2022

Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Bioavailability 52

Roots Analysis

MARCH 2, 2022

However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs. Web: [link].

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. The post Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3 appeared first on.

Drugs 52

Drugs Bioavailability Trials Clinical Development 52

Pharmaceutical Technology

AUGUST 10, 2022

The network comprises sites for the production of large-scale and controlled release oral solids in Winchester, Kentucky, development and manufacturing of softgel in St Petersburg, Florida, as well as other facilities with bioavailability enhancement technologies and platforms for oral solids production.

Packaging 147

Packaging Packaging Bioavailability Manufacturing 147

Drug Discovery World

JULY 27, 2022

Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP). . Now, the European Commission has granted REC-4881 Orphan Drug Designation. . As it stands there are no approved therapies for the disease. . Official comments .

Bioavailability 52

Bioavailability Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

NOVEMBER 27, 2023

Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met inhibitor. Apollomics is in active discussion with the US Food and Drug Administration (FDA) regarding a New Drug Application (NDA) for vebreltinib based on clinical data from the SPARTA trial and Avistone’s KUNPENG trial in China.

Bioavailability 52

Bioavailability Clinical Trials Clinical Trials Trials 52

Drug Discovery World

OCTOBER 12, 2022

Don’t miss your chance to register for the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. How FBDD is being used as one strategy of hit identification within drug discovery. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT.

Bioavailability 52

Bioavailability Drugs Medicine 52

Drug Discovery World

JULY 25, 2023

Justin Hay , Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects. In addition to describing the ethical framework (eg.

Development 52

Development Drugs Medicine Production 52

Drug Discovery World

MARCH 3, 2023

Using our proprietary GlyphTM platform, we have made natural allopregnanolone orally bioavailable without permanently chemically modifying the natural neurosteroid. Chief Medical Officer at PureTech.

Bioavailability 52

Bioavailability Trials Clinical Trials Clinical Trials 52

Roots Analysis

FEBRUARY 20, 2022

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Our Social Media Platform. Web: [link]. LinkedIn: [link].

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

The Pharma Data

JANUARY 7, 2021

While oral delivery route (62%) is still the most prevalent amongst marketed drug products, alternative adminstrations such as injection (22%), cutaneous, mucosal, inhalation, and others are making up a greater percentage as the industry works to improve bioavailability and subsequent efficacy.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

Drug Discovery World

NOVEMBER 29, 2023

Dr Kaplin said: “Unlike ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.

Development 52

Development Bioavailability Clinical Trials Clinical Trials 52

pharmaphorum

JULY 22, 2021

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ natural protein-denaturing machinery to remove rogue proteins associated with disease. billion in backloaded milestone payments.

Protein 114

Protein Hormones Bioavailability Drugs 114

Drug Discovery World

DECEMBER 16, 2022

A Phase I clinical study of STORM’s potential first-in-class candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, commenced treatment of cancer patients with solid tumours in November 2022. The post Biotech company raises $30M to target RNA modifying enzymes appeared first on Drug Discovery World (DDW).

RNA 52

RNA Immune Response Bioavailability Development 52

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Incentive Programs. Biowaiver Eligibility.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169